![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 29, 20060-20063, July 16, 1999
, andFrom the Department of Pharmacology, University of South Alabama, Mobile, Alabama 36688
| |
ABSTRACT |
|---|
|
|
|---|
The sequential binding of heat shock protein 90 (hsp90) to a series of tetratricopeptide repeat (TPR) proteins is
critical to its function as a molecular chaperone. We have used
site-directed mutagenesis to clarify the structural basis for the
binding of hsp90 to the TPR domain of phosphoprotein phosphatase 5 (PP5). This TPR domain was chosen for study because its
three-dimensional structure is known. We examined
co-immunoprecipitation of hsp90 with wild type and mutant TPR
constructs from transfected cells. Only mutations located on one face
of the TPR domain affected hsp90 binding. This allowed the
identification of a binding groove. Three basic residues that are
highly conserved in hsp90-binding TPR proteins extend prominently into
this groove. Lys-97 and Arg-101 were absolutely required for hsp90
binding, while mutation of Arg-74 diminished, but did not abrogate,
hsp90 binding. Mutation of Lys-32, another conserved basic residue in
the binding groove, also blocked hsp90 binding. The TPR domain of PP5
bound specifically to a 12-kDa C-terminal fragment of hsp90. This
binding was reduced by mutation of acidic residues in the hsp90
fragment. These data suggest conservation, among hsp90-binding TPR
proteins, of a binding groove containing basic residues that interact
with acidic residues near the C terminus of hsp90.
Heat shock protein
(hsp)1 90 is a molecular
chaperone necessary for viability (1) and for the proper folding,
processing, and function of proteins involved in several signal
transduction pathways (2). In perhaps the best characterized of these
pathways, association of steroid receptors with a series of hsp90
complexes is required for their acquisition of hormone-binding ability
(3). After hormone binding, steroid receptors are released from hsp90 and bind to DNA, activating transcription. hsp90 complexes are also
important for the folding of a variety of protein kinases and other
signal transducing proteins (2, 4-7). Recent data suggest that hsp90
may play an important role in facilitating evolution (8). Advances in
our understanding of the mechanisms of hsp90 action have raised the
possibility of using hsp90 and associated proteins as targets for
pharmacological intervention (9, 10).
Tetratricopeptide repeat (TPR) domains consist of tandem repeats of a
34-amino acid consensus sequence. These domains mediate protein-protein
interactions, and different TPR domains have different protein-binding
specificities (11). Several TPR proteins that bind to hsp90 play a
critical role in steroid receptor assembly (3). After newly synthesized
receptors bind to hsp70, Hop, a protein that binds to both hsp70 and
hsp90 via separate TPR domains, recruits hsp90 to the receptor complex.
Hop and hsp70 are then displaced by a large immunophilin (FKBP51,
FKBP52, or CyP-40) (12) that contains a TPR domain that binds to the
carboxyl end of hsp90 (13-15). These large immunophilins have
co-chaperone activity in vitro that does not involve their
peptidylprolyl isomerase activity and have biological activity
intrinsic to the TPR domain (16-18). Hop, in contrast, inhibits the
ATPase activity of hsp90 (19). Like hsp90, yeast homologues of Hop and
CyP-40 are required not only for optimal cell growth, but for optimal
signaling by recombinant steroid receptors and tyrosine kinases (18,
20, 21).
Mechanisms controlling which TPR proteins bind to hsp90, and when, are
clearly important. Binding of TPR proteins during protein folding
occurs in an ordered manner, and different large immunophilins associate preferentially with hsp90 complexes containing different steroid receptors (2). This has functional consequences,
e.g. glucocorticoid receptor complexes containing FKBP51
have lower binding affinity than complexes containing FKBP52 (22).
Understanding the structural basis for the binding of different TPR
proteins to hsp90 at different times will be important for
understanding its function as a molecular chaperone.
We have shown that PP5, a protein-serine phosphatase containing a TPR
domain at its N terminus (23-25), binds to hsp90 via its TPR domain
(26). PP5 is a major component of mature glucocorticoid receptor
complexes (27) and appears to regulate glucocorticoid receptor function
in vivo (26). These observations suggest that PP5 may act as
a co-chaperone for hsp90 and raise the possibility that protein
dephosphorylation may play a role in protein folding. The
three-dimensional structure of the TPR domain of PP5 was recently described (28). As predicted by the original papers describing TPR
domains (29, 30), the TPR domain of PP5 consists of six amphipathic We report here that four basic residues in the TPR domain, which are
conserved among PP5 and other hsp90-binding proteins, are critical for
binding to hsp90. These residues all lie along what we now definitively
identify as a binding groove. We also show that acidic residues in
hsp90 are required for optimal binding to the TPR domain of PP5.
Site-directed Mutagenesis of the TPR Domain of
PP5--
Mutagenesis with the Stratagene QuikChange kit was performed
according to the manufacturer's instructions, using the previously described pCMV6-FLAG-TPR (26) as a template. Mutants were sequenced to
confirm the presence of the desired mutations and the absence of
additional mutations. As an aid in choosing residues to mutate, the
three-dimensional structure of the PP5 TPR domain (28) was visualized
using the RasMol program.
Plasmid Construction--
Sequences encoding residues 628-732
of human hsp90
For expression as a fusion to the N terminus of GFP, sequences encoding
all but the C-terminal four amino acids (LGMM) of PP5 were excised from
pCMV6-FLAG-PP5 (26) as an EcoRI (blunted)/PstI fragment and cloned into the NheI (blunted)/PstI
sites of pEGFP-N1 (CLONTECH). Similarly, the
FLAG-tagged TPR domain was excised from pCMV6-FLAG-PP5 as an
EcoRI (blunted)/HindIII fragment and cloned into
the NheI (blunted)/HindIII sites of pEGFP-N1.
Tissue Culture and Transfections--
All cells were maintained
in Dulbecco's modified Eagle's medium containing 10% fetal bovine
serum. COS-7 cells were transfected using a DEAE-dextran method
(32).
Immunoprecipitation and Immunoblotting--
COS-7 cells in 35-mm
wells were transfected with the indicated plasmids. One day later,
cultures were incubated overnight in 1 ml of medium (90%
methionine-free, cysteine-free Dulbecco's modified Eagle's medium,
10% growth medium) containing 25 µCi of
[35S]methionine/cysteine (NEN Life Science Products, 1175 Ci/mmol). Cells were washed on ice with 20 mM HEPES, pH
7.4, 150 mM NaCl (HBS), and lysed in 1 ml of HBS containing
1% Triton X-100 and 10 µg/ml aprotinin. Lysates were clarified by
centrifugation at 2 °C for 15 min at 21,000 × g.
Clarified lysates were then subjected to immunoprecipitation using 1 µg of the monoclonal anti-FLAG antibody M2, followed by 20 µl of
goat anti-mouse IgG beads to collect immune complexes, as described
previously (26). After washes with lysis buffer, beads were heated in
SDS sample buffer, and samples were analyzed by SDS-PAGE and
fluorography (33). Aliquots of the same samples were analyzed by
immunoblotting with a monoclonal antibody to hsp90 as described
previously (26).
Binding to Bacterially Expressed Proteins--
Extracts of COS-7
cells, grown in 10-cm plates and transfected with the indicated
plasmids, were prepared as described above for immunoprecipitation and
aliquoted for binding to C90 fusion proteins.
Exponentially growing bacterial cultures were induced for 2-3 h at
37 °C with 0.1 mM
isopropyl-1-thio- Subcellular Fractionation--
Cells were fractionated as
described by Chen et al. (24), counting cells before
homogenization and nuclei after homogenization to ensure a lack of
nuclear lysis. Equal volumes of cytoplasmic and nuclear fractions were
analyzed by SDS-PAGE on an 8.5% gel followed by immunoblotting with
anti-PP5 serum as described previously (26).
Immunohistochemistry--
Cells were prepared for
immunohistochemistry using a 30-min paraformaldehyde fixation as
described by Chen et al. (24), using 1 µg/ml anti-PP5 IgG
and a 1:9000 dilution of goat anti-rabbit IgG conjugated to rhodamine
(Pierce 31672). In some experiments 2.5 µg of anti-PP5 IgG was
preadsorbed overnight at 4 °C with 5 µg of purified PP5 (26) or 5 µg of purified PP1 catalytic subunit (a gift from Dr. Thomas
Soderling, Oregon Health Sciences University). Cells were examined
using a Leica DMRB fluorescence microscope.
Confocal Microscopy--
COS-7 cells transfected with pEGFP-N1
vector, pEGFP-TPR, or pEGFP-PP5 were grown in a Lab-Tek four-chambered
coverglass system, and GFP in living cells was visualized using a
Meridian ACAS 570 laser scanning confocal microscope.
Identification of TPR Residues Required for hsp90
Binding--
Guided by the three-dimensional structure of the TPR
domain of PP5 (28), we performed charged-to-alanine scanning
mutagenesis. The scanning was not random in that we chose residues
whose side chains extended into the solvent, and that seemed unlikely,
therefore, to be critical for protein folding. In the first round of
mutagenesis (Fig. 1, left), we
mutated seven residues that are oriented along what has been suggested
to be a possible binding groove (28). COS-7 cells were transfected with
plasmids encoding the wild-type FLAG-tagged TPR domain or with plasmids
encoding the indicated mutant FLAG-tagged TPR domains. We then examined
co-immunoprecipitation of hsp90 with the various FLAG-tagged TPR
proteins from extracts of cells labeled with
[35S]methionine/cysteine. Extracts were analyzed by
SDS-PAGE and fluorography (Fig. 1, top left). As
we have shown previously, hsp90 co-immunoprecipitated specifically with
the wild-type TPR domain. The identity of hsp90 was confirmed by
immunoblotting with a monoclonal antibody (Fig. 1, bottom
left). Mutating Glu-29, Lys-40, Lys-130, or Glu-149 to
alanine had no significant effect on hsp90 co-immunoprecipitation. The
latter two residues lie beyond the TPR domain but are on the same face
of the protein as the putative binding groove (28). In contrast,
mutation of Arg-74, Lys-97, or Arg-101, which are highly conserved
among hsp90-binding TPR proteins and extend prominently into the
putative binding groove (28), led to markedly decreased hsp90 binding.
No co-immunoprecipitation of hsp90 was observed with the Lys-97 or
Arg-101 mutants, and co-immunoprecipitation was dramatically reduced
with the Arg-74 mutant. This experiment suggested that hsp90 binds to a
groove in the TPR domain and that three basic residues in this groove that are conserved among hsp90-binding TPR proteins are critical for
binding.
The above experiment tested only the importance of residues lying
within the groove in the TPR domain. In a second round of mutagenesis,
we also examined residues on different faces of the TPR domain (Fig. 1,
right). Mutation of Lys-32, located at one end of the
binding groove, completely abrogated hsp90 co-immunoprecipitation. Mutation of Ile-63, which is on the surface of the binding groove, reduced but did not eliminate hsp90 binding. This mutant was expressed at dramatically lower levels than the wild-type TPR domain and may be
improperly folded. Mutations of residues on the surface of the TPR
domain that are not in the groove (Glu-56, Cys-77, Tyr-80, Arg-113, and
Arg-117) had no effect on hsp90 co-immunoprecipitation. Thus, four
conserved basic residues in a groove within the TPR domain of PP5 are
essential for hsp90 binding, while other residues in this groove, and
residues on other faces of the TPR domain, are not required for this function.
Binding of the TPR Domain of PP5 to the C Terminus of
hsp90--
Several studies have shown an interaction between the
C-terminal domain of hsp90 and large immunophilins or Hop (13-15). As a first step toward identifying binding determinants in hsp90 that
interact with the TPR domain of PP5, we tested the ability of the
C-terminal 12-kDa domain of hsp90, designated C90 (as per Young
et al. (31)), to bind to this TPR domain. Extracts of COS
cells transfected with the wild-type FLAG-tagged TPR domain of PP5, or
with two mutants that failed to bind full-length hsp90, were incubated
with glutathione beads to which either control GST or a GST-C90 fusion
was bound. After washing away unbound material, samples were analyzed
by immunoblotting (Fig. 2A).
The wild-type TPR domain of PP5 bound specifically to GST-C90,
indicating that this portion of hsp90 is sufficient for binding. The
two PP5 mutants that did not bind to full-length hsp90 were also unable to bind to the C90 fragment (Fig. 2A).
Role of Acidic Residues in the C Terminus of hsp90 in Binding of
the TPR Domain of PP5--
Because basic residues in the TPR domain of
PP5 are critical for binding to hsp90, we hypothesized that acidic
residues in hsp90 would be important for its binding. Acidic residues
are distributed throughout the C90 fragment, but previous studies suggested that the C-terminal EEVD sequence might be of particular interest. This sequence is required for binding to Hop or CyP-40, and
its mutation reduces binding to FKBP51 or FKBP52 by one-half (13-15).
We tested, therefore, the effects of mutating these three acidic
residues to Ala or Lys. His-tagged C90 or C90 mutants were adsorbed to
beads and tested for their ability to bind to the FLAG-tagged TPR
domain. As controls, the Lys-97 and Arg-101 mutants of the TPR domain
were also tested, as was a double mutant in which both Lys-97 and
Arg-101 were mutated to Glu (Fig. 2B). The wild-type TPR
domain bound to His-tagged C90, as expected (Fig. 2B).
Binding to the C90 mutants was significantly reduced but not eliminated
(Fig. 2B). The TPR mutants did not bind to C90 or to either
C90 mutant. Thus, while C-terminal acidic residues of hsp90 are
important for optimal binding to the TPR domain of PP5, additional
binding determinants must exist. These results suggest that complex
formation occurs as a result of multiple interactions between basic
residues in the TPR domain of PP5 and acidic residues in the carboxyl
domain of hsp90.
Cytoplasmic Localization of PP5--
We performed the above
experiments based on our data suggesting that hsp90 and PP5 interact
in vivo (26). Chen et al. (24), however, have
suggested that PP5 is almost exclusively a nuclear protein, whereas
hsp90 is cytoplasmic. To address this discrepancy, we attempted to
reproduce the subcellular fractionation and immunofluorescence experiments of Chen et al. (24). When examined by
subcellular fractionation, PP5 was overwhelmingly cytoplasmic in either
HeLa cells or L929 cells (Fig.
3A). When examined by
immunofluorescence, PP5 was primarily cytoplasmic in HeLa cells (Fig.
3B), as well as in L929 and COS-7 cells (not shown). This
was not due to cross-reactivity of our antibody with cytoplasmic
phosphatases, because preadsorption of anti-PP5 with purified PP5
reduced cytoplasmic immunostaining, whereas preadsorption with purified
PP1 did not (Fig. 3B). Also, our PP5 antibody did not
cross-react with microgram amounts of PP1 or PP2A in immunoblotting
experiments (not shown). We conclude that PP5 is primarily a
cytoplasmic protein, and therefore that it is in the correct cellular
compartment to interact with hsp90 in vivo.
To examine this question further, GFP fusions of PP5 or its TPR domain
were expressed in COS-7 cells and examined by confocal microscopy (Fig.
3C). Control GFP was distributed uniformly throughout the
cell, but GFP fused to the TPR domain of PP5 or to full-length PP5 was
excluded from the nucleus. These results suggested that PP5 does not
contain a nuclear localization sequence.
In conjunction with the known three-dimensional structure of the
TPR domain of PP5 (28), our experiments have identified a binding
groove through which this domain binds to hsp90. Four basic amino acids
that protrude into this groove are essential for binding to either
full-length hsp90 or a 12-kDa C-terminal fragment of hsp90. This
carboxyl fragment of hsp90 is highly acidic; in the simplest model,
basic residues in the binding groove of the TPR domain of PP5 would be
predicted to interact with acidic residues at the carboxyl end of
hsp90. Because the basic residues important for hsp90 binding are
conserved in the TPR domains of other hsp90-binding proteins, they are
likely to be of general importance for the binding of TPR proteins to
hsp90. The observation that several acidic residues at the very C
terminus of hsp90 are important for maximal binding of several TPR
proteins including PP5 further supports a general role for conserved
basic residues in binding of TPR proteins to hsp90.
In the past, the significance of interactions between PP5 and hsp90 has
been questioned based on the cytoplasmic localization of hsp90 and the
apparent nuclear localization of PP5 (24). We were unable to reproduce
subcellular fractionation and immunofluorescence experiments suggesting
that PP5 is a nuclear protein; we find PP5 to be predominantly
cytoplasmic. In addition, fusions of PP5 or of its TPR domain to GFP
are excluded from the nucleus, indicating that PP5 lacks a nuclear
localization signal.
The TPR domain of PP5 is autoinhibitory (34), suggesting that it may
bind to the catalytic domain of PP5 in the basal state. In that case,
PP5 could be activated by a mechanism in which binding of hsp90
competitively displaced the TPR domain from the phosphatase catalytic
domain. If binding of the TPR domain to the catalytic domain involves
the same residues as binding to hsp90, then mutations in the TPR domain
that interfere with hsp90 binding would be predicted to result in
release of the TPR domain from the catalytic domain and increased basal
activity. Alternatively, the catalytic domain of PP5 may interact with
other residues in the binding groove or may bind to a different face of
the TPR domain. We are currently testing these hypotheses.
In addition to helping to identify the general mechanisms by which TPR
domains bind to hsp90, our results may be useful in the development of
compounds that disrupt hsp90 binding to specific TPR proteins.
Determination of the three-dimensional structures of hsp90 complexes
with these proteins will be necessary to determine the details of their
molecular interactions. Our identification of the hsp90-binding site in
the PP5 TPR domain, however, combined with the known structure of this
domain, may allow molecular modeling of TPR domains whose structure is
not yet known, and the rational synthesis of compounds that can compete
with hsp90 for binding to particular TPR proteins. This could be
important not only for hsp90-binding TPR proteins known to regulate
various signaling pathways, but also for less characterized TPR
proteins such as SGT/UBP, which regulates the assembly and release of
HIV and may also be involved in the parvovirus life cycle (35, 36).
Based on the sequence of this TPR protein, we would predict that its effects on viral pathogenesis involve binding to hsp90. Having identified the location of the residues involved in PP5 binding to
hsp90 may also be helpful in modeling how other TPR proteins interact
with their non-hsp90 partners.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
helices bundled together to form a globular domain. It has been
speculated that a groove on one face of this domain could form a
binding site for other proteins (28).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
, designated C90, were amplified by polymerase chain
reaction and cloned into pGEX-4T-1 (Amersham Pharmacia Biotech) as an
EcoRI/BamHI fragment, essentially as described by
Young et al. (31). Mutants of C90 in which the C-terminal
sequence was changed from EEVD to AAVA (C90
A3) or KKVK (C90
K3) were
prepared in a similar manner, using 3' primers encoding these
mutations. Each clone was sequenced to confirm the presence of the
desired mutations and the absence of additional mutations. C90 and the
two C90 mutants were also subcloned into pET30a (Novagen) as
EcoRI/BamHI fragments.
-D-galactopyranoside (TG-1 cells
carrying pGEX plasmids) or 1 mM
isopropyl-1-thio-
-D-galactopyranoside (BL21(DE3) cells
carrying pET plasmids). Pelleted cells were sonicated in HBS containing
25 mM benzamidine and 10 µg/ml each aprotinin and
leupeptin. Triton X-100 was then added to a final concentration of 1%,
and after incubation for 30 min at 4 °C, extracts were clarified by
centrifugation at 2 °C for 15 min at 21,000 × g. Aliquots of each clarified extract were incubated with
glutathione-Sepharose 4B beads or with His·Bind resin (Novagen), with
end-over-end rocking at 4 °C for 1 h. Beads were then washed
extensively with HBS/1% Triton X-100. COS-7 cell extracts were then
incubated with approximately 25 µl of washed beads for 1 h with
end-over-end rocking at 4 °C. As a positive control for expression
of the FLAG-tagged TPR proteins, extracts were incubated with 20 µl
of goat anti-mouse IgG beads to which 1 µg of M2 antibody had been
prebound. Beads were washed 5 times with 1 ml of HBS/1% Triton X-100
and heated in SDS sample buffer. Samples were analyzed by SDS-PAGE and
either staining with Coomassie Blue or immunoblotting using M2 antibody
as described previously (26).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (45K):
[in a new window]
Fig. 1.
Co-immunoprecipitation of hsp90 with mutants
of the FLAG-tagged TPR domain of PP5. COS-7 cells were transfected
with the indicated constructs, and the FLAG-tagged TPR domains were
immunoprecipitated with M2 antibody. Immunoprecipitates from cells
labeled with [35S]methionine/cysteine were analyzed by
SDS-PAGE and fluorography (top) or by immunoblotting with an
antibody to hsp90 (bottom).

View larger version (35K):
[in a new window]
Fig. 2.
Binding of FLAG-tagged TPR domain to the
C-terminal 12-kDa fragment of hsp90 (C90). Extracts of COS-7 cells
transfected with the indicated plasmids were incubated with beads to
which either GST-C90 or control GST had been prebound (A) or
beads to which His-tagged C90 or the indicated His-tagged C90 mutants
had been prebound (B). As a positive control for expression
of mutant TPR proteins, extracts were also incubated with beads to
which the M2 anti-FLAG antibody had been prebound (bottom
panel).

View larger version (70K):
[in a new window]
Fig. 3.
Subcellular localization of PP5.
A, nuclear (N) and cytoplasmic (C)
fractions of the indicated cells were analyzed by immunoblotting with
an antibody to PP5. B, HeLa cells were examined by
immunofluorescence with anti-PP5 (I) or preimmune
(PI) IgG. Where indicated, IgG was preadsorbed with an
excess of purified PP5 or PP1 catalytic subunit. C, COS-7
cells were transfected with plasmids encoding the indicated proteins
and examined by confocal laser scanning microscopy.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Drs. Mark Gillespie and Andrew Ramsey for careful reading of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants HL 47063 and DK 55877 (to M. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Dept. of Cell Biology and Physiology, Washington
University School of Medicine, St. Louis, MO 63110.
§ To whom correspondence should be addressed. Tel.: 334-460-6782; Fax: 334-460-6798; E-mail: michaelc@jaguar1.usouthal.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: hsp, heat shock protein; TPR, tetratricopeptide repeat; PP5, phosphoprotein phosphatase 5; GFP, green fluorescent protein; PAGE, polyacrylamide gel electrophoresis; GST, glutathione S-transferase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Parsell, D. A., and Lindquist, S. (1993) Annu. Rev. Genet. 27, 437-496[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Pratt, W. B. (1998) Proc. Soc. Exp. Biol. Med. 217, 420-434[Abstract] |
| 3. |
Pratt, W. B.,
and Toft, D. O.
(1997)
Endocr. Rev.
18,
306-360 |
| 4. | Chen, C.-F., Chen, Y., Dai, K., Chen, P.-L., Riley, D. J., and Lee, W. H. (1996) Mol. Cell. Biol. 16, 4691-4699[Abstract] |
| 5. |
Whitesell, L.,
Sutphin, P. D.,
Pulcini, E. J.,
Martinez, J. D.,
and Cook, P. H.
(1998)
Mol. Cell. Biol.
18,
1517-1524 |
| 6. | García-Cardeña, G., Fan, R., Shah, V., Sorrentino, R., Cirino, G., Papapetropoulos, A., and Sessa, W. C. (1998) Nature 392, 821-824[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Loo, M. A., Jensen, T. J., Cui, L., Hou, Y.-X., Chang, X.-B., and Riordan, J. R. (1998) EMBO J. 17, 6879-6887[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Rutherford, S. L., and Lindquist, S. (1998) Nature 396, 336-342[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Smith, D.,
Whitesell, L.,
and Katsanis, E.
(1998)
Pharmacol. Rev.
50,
493-513 |
| 10. | Scheibel, T., and Buchner, J. (1998) Biochem. Pharmacol. 56, 675-682[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Lamb, J. R., Tugendreich, S., and Hieter, P. (1995) Trends Biochem. Sci. 20, 257-259[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Frydman, J., and Höhfeld, J. (1997) Trends Biochem. Sci. 22, 87-92[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Chen, S., Sullivan, W. P., Toft, D. O., and Smith, D. F. (1998) Cell Stress & Chaperones 3, 118-129 [CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Young, J. C.,
Obermann, W. M. J.,
and Hartl, F. U.
(1998)
J. Biol. Chem.
273,
18007-18010 |
| 15. |
Carello, A.,
Ingley, E.,
Minchin, R. F.,
Tsai, S.,
and Ratajczak, T.
(1999)
J. Biol. Chem.
274,
2682-2689 |
| 16. |
Bose, S.,
Weikl, T.,
Bugl, H.,
and Buchner, J.
(1996)
Science
274,
1715-1717 |
| 17. |
Freeman, B. C.,
Toft, D. O.,
and Morimoto, R. I.
(1996)
Science
274,
1718-1720 |
| 18. |
Duina, A. A.,
Marsh, J. A.,
Kurtz, R. B.,
Chang, H.-C. J.,
Lindquist, S.,
and Gaber, R. F.
(1998)
J. Biol. Chem.
273,
10819-10822 |
| 19. | Prodromou, C., Siligardi, G., O'Brien, R., Woolfson, D. N., Regan, L., Panaretou, B., Ladbury, J. E., Piper, P. W., and Pearl, L. H. (1999) EMBO J. 18, 754-762[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Dolinski, K. J.,
Cardenas, M. E.,
and Heitman, J.
(1998)
Mol. Cell. Biol.
18,
7344-7352 |
| 21. |
Marsh, J. A.,
Kalton, H. M.,
and Gaber, R. F.
(1998)
Mol. Cell. Biol.
18,
7353-7359 |
| 22. |
Reynolds, P. D.,
Ruan, Y.,
Smith, D. F.,
and Scammell, J. G.
(1999)
J. Clin. Endocrinol. Metab.
84,
663-669 |
| 23. |
Chinkers, M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
11075-11079 |
| 24. | Chen, M. X., McPartlin, A. E., Brown, L., Chen, Y. H., Barker, H. M., and Cohen, P. T. W. (1994) EMBO J. 13, 4278-4290[Medline] [Order article via Infotrieve] |
| 25. |
Becker, W.,
Kentrup, H.,
Klumpp, S.,
Schultz, J. E.,
and Joost, H. G.
(1994)
J. Biol. Chem.
269,
22586-22592 |
| 26. |
Chen, M.-S.,
Silverstein, A. M.,
Pratt, W. B.,
and Chinkers, M.
(1996)
J. Biol. Chem
271,
32315-32320 |
| 27. |
Silverstein, A. M.,
Galigniana, M. D.,
Chen, M.-S.,
Owens-Grillo, J. K.,
Chinkers, M.,
and Pratt, W. B.
(1997)
J. Biol. Chem.
272,
16224-16230 |
| 28. | Das, A. K., Cohen, P. T. W., and Barford, D. (1998) EMBO J. 17, 1192-1199[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Sikorski, R., Boguski, M. S., Goebl, M., and Hieter, P. (1990) Cell 60, 307-317[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Hirano, T., Kinoshita, N., Morikawa, K., and Yanagida, M. (1990) Cell 60, 319-328[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Young, J. C., Schneider, C., and Hartl, F. U. (1997) FEBS Lett. 418, 139-143[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Cullen, B. R. (1987) Methods Enzymol. 152, 684-704[Medline] [Order article via Infotrieve] |
| 33. | Chamberlain, J. P. (1979) Anal. Biochem. 98, 132-135[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Chen, M. X., and Cohen, P. T. W. (1997) FEBS Lett. 400, 136-140[CrossRef][Medline] [Order article via Infotrieve] |
| 35. |
Cziepluch, C.,
Kordes, E.,
Poirey, R.,
Grewenig, A.,
Rommelaere, J.,
and Jauniaux, J.-C.
(1998)
J. Virol.
72,
4149-4156 |
| 36. |
Callahan, M. A.,
Handley, M. A.,
Lee, Y.-H.,
Talbot, K. J.,
Harper, J. W.,
and Panganiban, A. T.
(1998)
J. Virol.
72,
5189-5197 |
This article has been cited by other articles:
![]() |
S. J. Du, H. Li, Y. Bian, and Y. Zhong Heat-shock protein 90{alpha}1 is required for organized myofibril assembly in skeletal muscles of zebrafish embryos PNAS, January 15, 2008; 105(2): 554 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Allan, D. Mok, B. K. Ward, and T. Ratajczak Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90: EVIDENCE THAT COUMARIN ANTIBIOTICS DISRUPT Hsp90 DIMERIZATION J. Biol. Chem., March 17, 2006; 281(11): 7161 - 7171. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Carrigan, L. A. Sikkink, D. F. Smith, and M. Ramirez-Alvarado Domain:domain interactions within Hop, the Hsp70/Hsp90 organizing protein, are required for protein stability and structure Protein Sci., March 1, 2006; 15(3): 522 - 532. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Love and J. A. Hanover The Hexosamine Signaling Pathway: Deciphering the "O-GlcNAc Code" Sci. Signal., November 29, 2005; 2005(312): re13 - re13. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Conde, J. Xavier, C. McLoughlin, M. Chinkers, and N. Ovsenek Protein Phosphatase 5 Is a Negative Modulator of Heat Shock Factor 1 J. Biol. Chem., August 12, 2005; 280(32): 28989 - 28996. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Denny, V. Prapapanich, D. F. Smith, and J. G. Scammell Structure-Function Analysis of Squirrel Monkey FK506-Binding Protein 51, a Potent Inhibitor of Glucocorticoid Receptor Activity Endocrinology, July 1, 2005; 146(7): 3194 - 3201. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Carrigan, D. L. Riggs, M. Chinkers, and D. F. Smith Functional Comparison of Human and Drosophila Hop Reveals Novel Role in Steroid Receptor Maturation J. Biol. Chem., March 11, 2005; 280(10): 8906 - 8911. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Wochnik, J. Ruegg, G. A. Abel, U. Schmidt, F. Holsboer, and T. Rein FK506-binding Proteins 51 and 52 Differentially Regulate Dynein Interaction and Nuclear Translocation of the Glucocorticoid Receptor in Mammalian Cells J. Biol. Chem., February 11, 2005; 280(6): 4609 - 4616. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Huang, L. Shu, J. Easton, F. C. Harwood, G. S. Germain, H. Ichijo, and P. J. Houghton Inhibition of Mammalian Target of Rapamycin Activates Apoptosis Signal-regulating Kinase 1 Signaling by Suppressing Protein Phosphatase 5 Activity J. Biol. Chem., August 27, 2004; 279(35): 36490 - 36496. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. ISMAILI and M. J. GARABEDIAN Modulation of Glucocorticoid Receptor Function via Phosphorylation Ann. N.Y. Acad. Sci., June 1, 2004; 1024(1): 86 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Wu, P. Li, Y. Liu, Z. Lou, Y. Ding, C. Shu, S. Ye, M. Bartlam, B. Shen, and Z. Rao 3D structure of human FK506-binding protein 52: Implications for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplex PNAS, June 1, 2004; 101(22): 8348 - 8353. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Z. Gerges, I. C. Tran, D. S. Backos, J. M. Harrell, M. Chinkers, W. B. Pratt, and J. A. Esteban Independent Functions of hsp90 in Neurotransmitter Release and in the Continuous Synaptic Cycling of AMPA Receptors J. Neurosci., May 19, 2004; 24(20): 4758 - 4766. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Carrigan, G. M. Nelson, P. J. Roberts, J. Stoffer, D. L. Riggs, and D. F. Smith Multiple Domains of the Co-chaperone Hop Are Important for Hsp70 Binding J. Biol. Chem., April 16, 2004; 279(16): 16185 - 16193. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Cortajarena, T. Kajander, W. Pan, M. J. Cocco, and L. Regan Protein design to understand peptide ligand recognition by tetratricopeptide repeat proteins Protein Eng. Des. Sel., April 1, 2004; 17(4): 399 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. de la Fuente van Bentem, J. H. Vossen, J. E.M. Vermeer, M. J. de Vroomen, T. W.J. Gadella Jr., M. A. Haring, and B. J.C. Cornelissen The Subcellular Localization of Plant Protein Phosphatase 5 Isoforms Is Determined by Alternative Splicing Plant Physiology, October 1, 2003; 133(2): 702 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Takahashi, C. Casais, K. Ichimura, and K. Shirasu HSP90 interacts with RAR1 and SGT1 and is essential for RPS2-mediated disease resistance in Arabidopsis PNAS, September 30, 2003; 100(20): 11777 - 11782. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tesic, J. A. Marsh, S. B. Cullinan, and R. F. Gaber Functional Interactions between Hsp90 and the Co-chaperones Cns1 and Cpr7 in Saccharomyces cerevisiae J. Biol. Chem., August 29, 2003; 278(35): 32692 - 32701. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. B. Bolger, A. H. Peden, M. R. Steele, C. MacKenzie, D. G. McEwan, D. A. Wallace, E. Huston, G. S. Baillie, and M. D. Houslay Attenuation of the Activity of the cAMP-specific Phosphodiesterase PDE4A5 by Interaction with the Immunophilin XAP2 J. Biol. Chem., August 29, 2003; 278(35): 33351 - 33363. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Hubler, W. B. Denny, D. L. Valentine, J. Cheung-Flynn, D. F. Smith, and J. G. Scammell The FK506-Binding Immunophilin FKBP51 Is Transcriptionally Regulated by Progestin and Attenuates Progestin Responsiveness Endocrinology, June 1, 2003; 144(6): 2380 - 2387. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cheung-Flynn, P. J. Roberts, D. L. Riggs, and D. F. Smith C-terminal Sequences outside the Tetratricopeptide Repeat Domain of FKBP51 and FKBP52 Cause Differential Binding to Hsp90 J. Biol. Chem., May 2, 2003; 278(19): 17388 - 17394. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Urban, T. Golden, I. V. Aragon, L. Cowsert, S. R. Cooper, N. M. Dean, and R. E. Honkanen Identification of a Functional Link for the p53 Tumor Suppressor Protein in Dexamethasone-induced Growth Suppression J. Biol. Chem., March 7, 2003; 278(11): 9747 - 9753. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. O. Odunuga, J. A. Hornby, C. Bies, R. Zimmermann, D. J. Pugh, and G. L. Blatch Tetratricopeptide Repeat Motif-mediated Hsc70-mSTI1 Interaction. MOLECULAR CHARACTERIZATION OF THE CRITICAL CONTACTS FOR SUCCESSFUL BINDING AND SPECIFICITY J. Biol. Chem., February 21, 2003; 278(9): 6896 - 6904. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Pratt and D. O. Toft Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery Experimental Biology and Medicine, February 1, 2003; 228(2): 111 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Ward, R. K. Allan, D. Mok, S. E. Temple, P. Taylor, J. Dornan, P. J. Mark, D. J. Shaw, P. Kumar, M. D. Walkinshaw, et al. A Structure-based Mutational Analysis of Cyclophilin 40 Identifies Key Residues in the Core Tetratricopeptide Repeat Domain That Mediate Binding to Hsp90 J. Biol. Chem., October 18, 2002; 277(43): 40799 - 40809. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dubacq, R. Guerois, R. Courbeyrette, K. Kitagawa, and C. Mann Sgt1p Contributes to Cyclic AMP Pathway Activity and Physically Interacts with the Adenylyl Cyclase Cyr1p/Cdc35p in Budding Yeast Eukaryot. Cell, August 1, 2002; 1(4): 568 - 582. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Siligardi, B. Panaretou, P. Meyer, S. Singh, D. N. Woolfson, P. W. Piper, L. H. Pearl, and C. Prodromou Regulation of Hsp90 ATPase Activity by the Co-chaperone Cdc37p/p50cdc37 J. Biol. Chem., May 31, 2002; 277(23): 20151 - 20159. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Brinker, C. Scheufler, F. von der Mulbe, B. Fleckenstein, C. Herrmann, G. Jung, I. Moarefi, and F. U. Hartl Ligand Discrimination by TPR Domains. RELEVANCE AND SELECTIVITY OF EEVD-RECOGNITION IN Hsp70{middle dot}Hop{middle dot}Hsp90 COMPLEXES J. Biol. Chem., May 24, 2002; 277(22): 19265 - 19275. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Barral, A. H. Hutagalung, A. Brinker, F. U. Hartl, and H. F. Epstein Role of the Myosin Assembly Protein UNC-45 as a Molecu |